Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences and keeping the price target at $125.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors including Gilead Sciences’ recent financial performance and future growth prospects. The company reported a 4% earnings per share (EPS) beat, attributed to effective cost management and strong performance in its HIV and liver segments. This was despite some declines in other areas like cell therapy and Veklury sales. Additionally, Gilead’s total revenue exceeded expectations, coming in at $7.77 billion, which was 5% above consensus estimates.
Looking ahead, Gilead has slightly raised its 2025 sales guidance, now anticipating a 5% year-over-year growth in HIV sales, driven by the strength of products like Biktarvy and Descovy. The company is also optimistic about the launch of Yeztugo, projecting significant sales growth by 2025. These positive indicators, along with favorable foreign exchange conditions and strategic cost controls, support Van Buren’s Buy rating for Gilead Sciences.